MUMBAI, Oct 3 (Reuters) - TCG Lifesciences Ltd plans to sell
9.5 million shares through an initial public offer and has filed
the draft red herring prospectus with the market regulator for
the same.
The proposed issue would constitute 14.41 percent of the
company's fully diluted post-issue capital and the proceeds from
the same would be used to fund its capital expenditure and repay
debts, it said in a statement.
The book running lead managers to the issue are Kotak
Mahindra Capital and Enam Financial Consultants.
The company is also looking at a pre-IPO placement of 1.5
million shares with some investors and if the deal goes through,
it may consider reducing the size of the IPO commensurately, the
statement said.
TCG Lifesciences offers solution in discovery research,
clinical development and enterprise informatics and its clients
include most of the top global pharmaceutical companies, it said.
((Reporting by Kaustav Roy, editing by Sunil Nair; Reuters
Messaging: [email protected],
+91-22-6636-9000))
Keywords: TCG IPO/